ESR1 and breast carcinoma: Among breast cancer subtypes, TNBC is an aggressive subtype characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), resulting in limited therapeutic options and poorer outcomes (Bianchini et al., 2022).